Rare genetic diseases of obesity present with a variety of clinical characteristics such as hypothyroidism, hypogonadism, renal abnormalities, and developmental delays.1
However, 2 hallmark symptoms common to many of these rare genetic diseases help separate them from more common forms of obesity:1,6

  • Early-onset, severe obesity
  • Hyperphagia

More information on Hallmark Symptoms of Bardet-Biedl syndrome (BBS)


What to look for

Early-onset, severe obesity:

Some forms of obesity are caused by genetic variants in a key neurosignaling pathway in the hypothalamus responsible for regulating hunger (the MC4R pathway).1,2

A BMI curve well above reference percentiles as shown in the graph may indicate an underlying rare genetic disease of obesity.21

BMI curves indicating underlying rare genetic diseases of obesity

Hyperphagia:

These patients present with defining behaviors, including:22,23

Heightened and prolonged hunger

Heightened and prolonged hunger

Longer time to reach satiety

Longer time to reach satiety

Shorter duration of satiety

Shorter duration of satiety

Severe preoccupation with food

Severe preoccupation with food

Excessive food-seeking behaviors

Excessive food-seeking behaviors (night eating, stealing food, foraging for food in trash)

Significant distress and inappropriate response if denied food

Significant distress and inappropriate response if denied food

Searching for answers

“Joshua was born a normal weight but continued gaining weight right from the start. He gained 6 pounds between a 4- and a 6-month checkup. He is just continually feeling hungry.

Molly

Mom to Joshua, living with Bardet-Biedl Syndrome

If you suspect a patient may be experiencing hyperphagia

Below are some common questions to ask:

For patients

Sleep
Do you wake up asking or searching for food during the night?
If so, how does this affect your sleep?

Mood
Do you ever feel hungry after you just ate?
Do you ever feel stressed out due to hunger, or worry about food?

School/work
How does hunger impact your ability to concentrate at school or work?

Recreational activities
Has hunger ever impacted your ability to participate in recreational activities?

Relationships with family/friends
How does hunger impact your relationships with family or friends?

For caregivers

Sleep
Does the patient wake up asking or searching for food during the night?
How does this affect the patient’s sleep?
How does this affect you?

Mood
How does hunger impact the patient’s mood?
Does the patient feel stressed due to food?
How does this affect you getting things done at home or at work?

School/work
Does hunger impact the patient’s ability to concentrate at school or work? How?

Recreational activities
Does hunger impact the patient’s ability to participate in recreational activities?

Relationships with family/friends
How does hunger impact the patient’s relationships with other family members/friends?
Have you had any uncomfortable or strained interactions with your family or friends due to your child’s hunger?


Diagnosing rare genetic diseases of obesity

Some rare genetic diseases of obesity can be diagnosed clinically, while genetic testing can aid in the diagnosis of others.6,7

Clinically diagnosed (Syndromic)

Certain syndromic rare genetic diseases of obesity can be diagnosed clinically based on specific clinical characteristics. In addition to early-onset, severe obesity and hyperphagia, these diseases can also present with visual impairment, cognitive impairment, postaxial polydactyly, renal anomalies, hypogonadism, or other possible clinical characteristics.1

Explore diagnosis of:

Bardet-Biedl syndrome

Alström syndrome

Genetic testing may also help confirm a suspected clinical diagnosis.

Genetically identifiable (Non-Syndromic)

For non-syndromic rare genetic diseases of obesity, genetic testing can help you and your patients better understand a primary cause of their obesity by identifying relevant genetic variants.

This knowledge can inform:

  • Possible diagnosis
  • Appropriate disease management options
  • Potential eligibility for clinical studies

Patients and families often gain a great sense of relief in knowing there is an underlying cause of their obesity unrelated to environmental and lifestyle factors.

Explore more about:

Genetic testing may lead to diagnosis, options and relief
Genetic testing may lead to diagnosis, options and relief

“We suggest genetic testing in patients with extreme early-onset obesity (before 5 years of age) and that have clinical features of genetic obesity syndromes (in particular extreme hyperphagia) and/or a family history of extreme obesity.” 6

“Genetic testing recommended with clinical features such as extreme hyperphagia and/or family history of extreme obesity.” 7

Genetic testing program

Uncovering Rare Obesity® is a no-charge, comprehensive genetic testing program for rare genetic diseases of obesity.

Rhythm Pharmaceuticals covers the cost of the test and provides sample collection kits. Patients are responsible for any office visit, sample collection, or other costs.

Explore testing opportunities

LEPR=leptin receptor; MC4R=melanocortin-4 receptor; PCSK1=proprotein convertase subtilisin/kexin type 1; POMC=proopiomelanocortin; SH2B1=SH2B adaptor protein 1; SRC1=steroid receptor coactivator-1.


  • References
    1. Huvenne H, Duberne B, Clément K, Poitou C. Rare genetic forms of obesity: clinical approach and current treatments in 2016. Obes Facts. 2016;9(3):158-173.

    2. Ellacott KL, Cone RD. The role of the central melanocortin system in the regulation of food intake and energy homeostasis: lessons from mouse models. Philos Trans R Soc Land B Biol Sci. 2006;361(1471):1265-1274.

    3. Hales CM, Fryar CD, Carroll MD, Freedman DS, Ogden CL. Trends in obesity and severe obesity prevalence in US youth and adults by sex and age,
      2007-2008 to 2015-2016. JAMA. 2018;319(16):1723-1725.

    4. Ward ZJ, Long MW, Resch SC, Giles CM, Cradock AL, Gortmaker SL. Simulation of growth trajectories of childhood obesity into adulthood. N Engl J Med.
      2017;377(22):2145-2153.

    5. Data on file. Rhythm Pharmaceuticals, Inc. Boston, MA.

    6. Styne DM, Arslanian SA, Connor EL, et al. Pediatric obesity-assessment, treatment, and prevention: an Endocrine Society clinical practice guideline. J Clin
      Endocrinol Metab. 2017;102(3);709-757.

    7. Cuda S, Censani M, O’Hara V, et al. Pediatric Obesity Algorithm eBook. Obesity Medicine Association. 2020-2022.
      http://www.obesitymedicine.org/childhood-obesity. Accessed June 8, 2021.

    8. Morton GJ, Meek TH, Schwartz MW. Neurobiology of food intake in health and disease. Nat Rev Neurosci. 2014;15(6):367-378.

    9. van der Klaauw AA, Farooqi IS. The hunger genes: pathways to obesity. Cell. 2015;161(1):119-132.

    10. da Fonseca ACP, Mastronardi C, Johar A, Arcos-Burgos M, Paz-Filho G. Genetics of non-syndromic childhood obesity and the use of high-throughput DNA sequencing technologies. J Diabetes Complications. 2017;31(10):1549-1561.

    11. Yazdi FT, Clee SM, Meyre D. Obesity genetics in mouse and human: back and forth, and back again. PeerJ. 2015;3:e856.

    12. Burns B, Schmidt K, Williams SR, Kim S, Girirajan S, Elsea SH. Rai1 haploinsufficiency causes reduced Bdnf expression resulting in hyperphagia, obesity and altered fat distribution in mice and humans with no evidence of metabolic syndrome. Hum Mol Genet. 2010;19(20):4026-4042.

    13. Lu Q, Yang Y, Jia S, et al. SRC1 deficiency in hypothalamic arcuate nucleus increases appetite and body weight. J Mol Endocrinol. 2018:JME-18-0075.R2.

    14. Vaisse C, Reiter JF, Berbari NF. Cilia and obesity. Cold Spring Harb Perspect Biol. 2017;9(7):a028217.

    15. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405-424.

    16. Sequencing Sample Reports: Indeterminate (with CNV). Prevention Genetics. Updated October 18, 2009. https://www.preventiongenetics.com/ClinicalTesting/TestCategory/sampleReports. Accessed November 11, 2021.

    17. A guide to understanding variant classification. Blueprint Genetics. https://blueprintgenetics.com/wp-content/uploads/2020/10/Variant_Classification_WP_VARA41-06-FINAL.pdf. Accessed November 11, 2021

    18. VUS – the most maligned result in genetic testing. Blueprint Genetics. Updated October 29, 2020. https://blueprintgenetics.com/resources/vus-the-most-maligned-result-in-genetic-testing/. Accessed November 11, 2021.

    19. Bean LJH, Tinker SW, da Silva C, Hegde MR. Free the data: one laboratory’s approach to knowledge-based genomic variants classification and preparation for EMR integration of genomic data. Hum Mutat. 2013;34:1183-1188.

    20. Online Mendelian Inheritance in Man. Entries 609734, 600955, and 614963. https://www.omim.org/. Accessed November 18, 2021.

    21. Kohlsdorf K, Nunziata A, Funcke JB, et al. Early childhood BMI trajectories in monogenic obesity due to leptin, leptin receptor, and melanocortin 4 receptor deficiency. Int J Obes (Lond). 2018;42(9):1602-1609.

    22. Heymsfield SB, Avena NM, Baier L, et al. Hyperphagia: current concepts and future directions proceedings of the 2nd international conference on hyperphagia. Obesity (Silver Spring). 2014;22 Suppl 1(0 1):S1-S17.

    23. Shah BP, Moeller IH, Van der Ploeg LHT, Garfield AS. Identification and functional characterization of novel variants in genes in the MC4R pathway associated with severe early-onset obesity and hyperphagia. Oral presentation at: Keystone Symposia. February 2019. Banff, Alberta, Canada.

    24. Rhythm 10-K Annual Report (2020). Rhythm Pharmaceuticals. Accessed November 11, 2021.

    25. Ayers KL, Glicksberg BS, Garfield AS, et al. Melanocortin 4 Receptor pathway dysfunction in obesity: patient stratification aimed at MC4R agonist treatment. J Clin Endocrinol Metab. 2018;103:2601-2612.

    26. Forsythe E, Kenny J, Bacchelli C, Beales PL. Managing Bardet-Biedl syndrome—now and in the future. Front Pediatr. 2018;6:23.

    27. Forsythe E, Beales PL. Bardet-Biedl syndrome. Eur J Hum Genet. 2013;21(1):8-13.

    28. Pigeyre M, Yazdi FT, Kaur Y, Meyre D. Recent progress in genetics, epigenetics and metagenomics unveils the pathophysiology of human obesity. Clin Sci (Lond). 2016;130(12):943-986.

    29. Sherafat-Kazemzadeh R, Ivey L, Kahn SR, et al. Hyperphagia among patients with Bardet-Biedl syndrome. Pediatr Obes. 2013;8(5):e64-e67.

    30. Joy T, Cao H, Black G, et al. Alström syndrome (OMIM 203800): a case report and literature review. Orphanet J Rare Dis. 2007;2:49.

    31. Van Groenendael S, Giacovazzi L, Davison F, et al. High quality, patient centred and coordinated care for Alstrom syndrome: a model of care for an ultra-rare disease. Orphanet J Rare Dis. 2015;10:149.

    32. Waters AM, Beales PL. Ciliopathies: an expanding disease spectrum. Pediatr Nephrol. 2011;26:1039.

    33. Paisey RB, Steeds R, Barrett T, et al. Alström Syndrome. GeneReviews®. February 7, 2003. Updated June 13, 2019. https://www.ncbi.nlm.nih.gov/books/NBK1267/. Accessed November 10, 2021.

    34. Coll AP, Farooqi SI, Challis BG, Yeo GSH, O’Rahilly S. Proopiomelanocortin and energy balance: insights from human and murine genetics. J Clin Endocrinal Metab. 2004,89:2557.

    35. Mendiratta MS, Yang Y, Balazs AE, et al. Early onset obesity and adrenal insufficiency associated with a homozygous POMC mutation. Int J Pediatr Endocrinal. 2011;5.

    36. National Institutes of Health. POMC deficiency. MedlinePlus®. Updated August 18, 2020. https://medlineplus.gov/genetics/condition/proopiomelanocortin-deficiency/. Accessed November 10, 2021.

    37. Farooqi IS, Wangensteen T, Collins S, et al. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med. 2007;356:237.

    38. Stijnen P, Ramos-Molina B, O’Rahilly S, et al. PCSK1 mutations and human endocrinopathies: from obesity to gastrointestinal disorder. Endocr Rev. 2016;37(4):347-371.

    39. Martin MG, Lindberg I, Solorzano-Vargas RS, et al. Congenital proprotein convertase 1/3 deficiency causes malabsorptive diarrhea and other endocrinopathies in a pediatric cohort. Gastroenterology. 2013;145(1):138-148.

    40. Rui L. SH2B1 regulation of energy balance, body weight, and glucose metabolism. World J Diabetes. 2014;5:511.

    41. Doche ME, Bochukova EG, Su HW, et al. Human SH2B1 mutations are associated with maladaptive behaviors and obesity. J Clin Invest. 2012;122:4732.

    42. Yang Y, van der Klaauw AA, Zhu L, et al. Steroid receptor coactivator-1 modulates the function of Pomc neurons and energy homeostasis. Nat Commun. 2019;10:1718.

    43. Cacciottolo TM, Perikari A, van der Klaauw A, et al. Rare variants in Steroid Receptor Coactivator-1 (SRC-1) associated with obesity, adipose tissue dysfunction and liver fibrosis. QJM. 2019;112(9);724-729.

    44. National Institutes of Health. Bardet-Biedl syndrome. MedlinePlus®. Updated August 18, 2020. https://medlineplus.gov/genetics/condition/bardet-biedl-syndrome/#inheritance. Accessed June 15, 2021.

    45. Pomeroy J, Krentz AD, Richardson JG, et al. Bardet-Biedl syndrome. Pediatr Obes. 2021;16:e12703.

    46. Forsythe E, Sparks K, Hoskins BE, et al. Genetic predictors of cardiovascular morbidity in Bardet-Biedl syndrome. Clin Genet. 2015;87(4):343-349.

    47. Vos N, Oussaada S, Cooiman MI, et al. Bariatric surgery for monogenic non-syndromic and syndromic obesity disorder. Curr Diab Rep. 2020;20(44):1-10.

    48. Kenny J, Forsythe E, Beales P, Bacchelli C. Toward personalized medicine in Bardet-Biedl syndrome. Per Med. 2017;14(5):447-456.

    49. Poitou C, Mosbah H, Clement K. Mechanisms in endocrinology: update on treatments for patients with genetic obesity. Eur J Endocrinol. 2020;183(5):R149-R166.

    50. Srivastava G, Apovian CM. Current pharmacotherapy for obesity. Nat Rev Endocrinol. 2018;14(1):12-24.

    51. Beales PL, Elcioglu N, Woolf AS, Parker D, Flinter FA. New criteria for improved diagnosis of Bardet-Biedl syndrome: results of a population survey. J Med Genet. 1999;36(6):437-446.

    52. Forsyth R, Gunay-Aygun M. Bardet-Biedl syndrome overview. GeneReviews®. July 14, 2003. Updated July 23, 2020. https://www.ncbi.nlm.nih.gov/books/NBK1363/. Accessed November 10, 2021.

    53. Alvarez-Satta M, Castro-Sanchez C, Valverde D. Alström syndrome: current perspectives. Appl Clin Genet. 2015;8:171-179.

    54. Nordang GBN, Busk OL, Tveten K, et al. Next-generation sequencing of the monogenic obesity genes LEP, LEPR, MC4R, PCSK1 and POMC in a Norwegian cohort of patients with morbid obesity and normal weight controls. Mol Genet Metab. 2017;121:51.

    55. Aliferis K, Helle S, Gyapay G, et al. Differentiating Alström from Bardet-Biedl syndrome (BBS) using systemic ciliopathy genes sequencing. Ophthalmic Genet. 2012;33(1): 18-22.

    56. Eneli I, Xu J, Webster M, et al. Tracing the effect of the melanocortin-4 receptor pathway in obesity: study design and methodology of the TEMPO registry. Appl Clin Genet. 2019;12:87-93.

    57. Seo S, Guo DF, Bugge K, Morgan DA, Rahmouni K, Sheffield VC. Requirement of Bardet-Biedl syndrome proteins for leptin receptor signaling. Hum Mol Genet. 2009;18(7):1323-1331.

    58. Courbage S, Poitou S, Le Beyec – Le Bihan J, et al. Implication of heterozygous variants in genes of the leptin-melanocortin pathway in severe obesity. J Clin Endocrinol Metab. 2021;106(10):2991-3006.